Automated serology with recombinant allergens. A feasibility study

Area of Science:

• Immunology
• Allergology
• Biotechnology

Background:

• Current allergic condition diagnosis relies on skin tests and serology using allergenic preparations.
• The quality of allergenic substances and patient reactivity significantly impact diagnostic test results.
• Recombinant allergens offer high purity and potential for improved diagnostic accuracy in allergic diseases.

Purpose of the Study:

• To evaluate the diagnostic utility of recombinant Aspergillus fumigatus allergen I (rAsp f I/a) in automated serology.
• To assess the feasibility of integrating recombinant allergens into the Pharmacia CAP System for allergy diagnosis.
• To determine if rAsp f I/a retains its antigenic activity when immobilized for ImmunoCAPs.

Main Methods:

• Production of ImmunoCAPs with immobilized rAsp f I/a.
• Evaluation of ImmunoCAPs using sera from patients with allergic bronchopulmonary aspergillosis (ABPA), allergic asthma, and healthy controls.
• Comparison of IgE antibody detection using direct antigen-specific ELISA and the new rAsp f I/a ImmunoCAPs.

Main Results:

• Quantitative results from ELISA and rAsp f I/a ImmunoCAPs showed a close correlation.
• Immobilized rAsp f I/a demonstrated unaltered antigenic activity within the Pharmacia CAP System.
• The study confirms the feasibility of using rAsp f I/a in automated serological diagnostic platforms.

Conclusions:

• Recombinant Aspergillus fumigatus allergen I (rAsp f I/a) is suitable for incorporation into the Pharmacia CAP System.
• Recombinant allergens hold significant promise for the automated diagnosis of allergic conditions.
• Further evaluation of various recombinant Aspergillus fumigatus allergens is planned for automated diagnostics.